November 2020 - Page 2 of 3 - PsychedelicNewsWire (PNW)

WednesdayNov 18, 2020 11:56 am

Pure Extracts Technologies Corp. (CSE: PULL) Now Trading on the Canadian Securities Exchange Under “PULL” Symbol

Pure Extracts trading on CSE under “PULL” symbol Pure Extracts cannabis and hemp industry verticals include toll processing, white labeling and developing its own private label of cannabis products Pure Extracts is entering the functional mushroom market Company’s CO2 extraction facility complies with European Union GMP standards - intends to seek EU GMP certification for exports to Europe Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently announced that the Company’s stock is now trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL”. “Our trading debut on the…

TuesdayNov 17, 2020 3:00 pm

Psychedelics Alter How Humans Recognize Facial Emotions

According to a systematic review that was reported in Therapeutic Advances in Psychopharmacology, psychedelic drugs such as LSD and mescaline decrease the recognition of negative facial expressions. Generally, the main facial expressions characterizing basic human emotions are happiness, sadness, surprise, disgust, fear and anger. The psychedelic substances do this by adjusting the amygdala’s activity, which is the region of the brain that drives a person’s flight or fight response. A postdoctoral fellow at the University of Sao Paulo, Rafael Guimarães dos Santos, who is the study’s author, explained that they’d been looking into the effects of ayahuasca on humans for…

MondayNov 16, 2020 3:15 pm

Opioid Drugs Approved in Last Two Decades Lack Sufficient Safety Assessments

Researchers from George Washington University and the Johns Hopkins Bloomberg School have discovered that the data used to approve opioid pain medications by the FDA from 1997 to 2018 depended on intermediate or short-term studies that largely didn’t sufficiently examine safety outcomes. The findings, which were obtained from a cross-sectional analysis, were reported in the “Annals of Internal Medicine.” The safety assessment and study details for every drug were examined. The investigators also amassed all 48 new drug applications for opioid goods that had been approved by the U.S. FDA for the treatment of chronic or acute pain. Among the…

FridayNov 13, 2020 3:24 pm

How Intravenous Ketamine Use Helps Manage and Treat Depression

Patients with treatment resistant depression tolerate ketamine therapy well, with many recording improvements in their depressive symptomatology score (QIDS-SR16) A chart review was carried out among patients with treatment resistant depression who were being treated at the Massachusetts General Hospital Intravenous Ketamine Clinic for Depression, on an outpatient basis. The study results were then published in the “Journal of Affective Disorders.” The researchers assessed the outcomes different outpatients experienced at the ketamine clinic between October 2018 and November 2019. The study involved 85 patients with treatment resistant depression. Before IV ketamine was administered during every visit, the severity of the…

FridayNov 13, 2020 10:46 am

Rritual Superfoods Gains Important USDA Organic Certification for Emerging Industry Superfood Elixirs

Plant-based superfood developer Rritual Superfoods Inc. gained certification from the USDA validating its organic product marketing recently, helping to establish the company’s premium functional food elixirs following their launch in September The initial three product line elixirs, shots and mixes promote wellness by blending select nutraceutical mushrooms with adaptogenic roots to promote the body’s immune and cognitive function, as well as to reduce stress Market analysts predict the overall functional foods industry will achieve revenues of $268 billion by 2027 Functional mushrooms are a still-emerging subsector within the industry, allowing Rritual opportunity to build a following from the ground floor…

ThursdayNov 12, 2020 3:30 pm

Patients with Depression Can Pay for Psychedelic Treatment in Netherlands

Recent discoveries have shown psychedelics to possess many benefits, some of which are known and others that are yet to be discovered. Among those that are known is the discovery that psilocybin can be used to treat depression. Psilocybin, sometimes dubbed magic mushrooms, also helps manage alcohol addiction. Research has shown that when psilocybin therapy is administered to a patient who has depression, it can take months for mild symptoms to reappear again. Over time however, if the therapy isn’t re-administered, the symptoms slowly return. Many governments across the globe have documented various illegal drugs, and in many countries, psychedelics…

WednesdayNov 11, 2020 3:20 pm

No Existing Evidence Suggests Psychedelics Can Alter Religious, Political Beliefs

As psychedelics slowly become more mainstream, some alarmist and exaggerated views of the substances may also be resurfacing. To help give a more grounded perspective, scientific data is used to discredit these extreme views. Today, we look into an article that was published approximately a month ago that argues whether a psychedelic pill can change a person’s religious or political beliefs. The piece brings up ethical questions addressing whether psychedelics ar as effective as psychiatric treatments. The author, Eddie Jacobs, argues that psychedelic therapy may shift a patient’s religious beliefs or political beliefs in another direction. However, this theory is…

TuesdayNov 10, 2020 3:30 pm

What You Should Know About Microdosing Psychedelics

Microdosing is basically consuming a small dose of a psychedelic substance. The dose is normally 5% to 10% of the normal dose of a psychedelic substance. The microdose is consumed on every third day with two days off between dose days. To prevent habitual use and psychological dependence, users should stop usage at the end a month’s period. The most popular psychedelics used for microdosing are psilocybin and LSD. Other compounds that can be consumed at microdose levels include ibogaine, DMT, ayahuasca and mescaline. To make each dose consistent, microdosers may grind the dried fungi or plant because potency varies…

MondayNov 09, 2020 10:45 am

Oregonians Approve Measure to Legalize Psilocybin Therapy

Voters in Oregon have approved a psilocybin ballot initiative, with 1,193,632 people voting yes on the measure and 947,650 individuals voting no. The initiative legalizes psilocybin mushroom use for therapeutic purposes. Under the initiative, adults will be able to acquire psychedelic treatment in an environment that is medically supervised. The measure has no limitations on the conditions required for an individual to be eligible for treatment. Presently, no policies such as this exist in any other state in the United States, although the victory does come at a time when a national movement calling for the decriminalization of various entheogenic…

FridayNov 06, 2020 3:04 pm

Rritual Mushrooms Lauded for Attractive Product Marketing and Growth During Annual Awards

Plant-based superfood developer Rritual Mushrooms Inc. has produced its initial product lineup of three functional mushroom elixirs and powders designed to boost personal wellness The company was recognized by retail marketing agency ECRM for its attractive product presentation and growing success, as judged by national outlets including CVS, Vitamin Shoppe, Amazon and Rite Aid The functional mushroom market is a nascent subsection of the wellness industry ripe with potential for companies that get in on the ground floor as expectations for the industry grow Rritual’s Reishi Relax, Chaga Immune and Lion's Mane Focus formulations are available in 14-stick packs and…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: November 2020